SG11201405563VA - Imidazo [1, 2 - b] pyridazine - based compounds, compositions comprising them, and uses thereof - Google Patents

Imidazo [1, 2 - b] pyridazine - based compounds, compositions comprising them, and uses thereof

Info

Publication number
SG11201405563VA
SG11201405563VA SG11201405563VA SG11201405563VA SG11201405563VA SG 11201405563V A SG11201405563V A SG 11201405563VA SG 11201405563V A SG11201405563V A SG 11201405563VA SG 11201405563V A SG11201405563V A SG 11201405563VA SG 11201405563V A SG11201405563V A SG 11201405563VA
Authority
SG
Singapore
Prior art keywords
imidazo
pyridazine
compositions
based compounds
compounds
Prior art date
Application number
SG11201405563VA
Other languages
English (en)
Inventor
Yingzhi Bi
Kenneth Gordon Carson
Giovanni Cianchetta
Michael Alan Green
Godwin Kumi
Zhi Liang
Ying Jade Liu
Alan Main
Yulian Zhang
Glenn Gregory Zipp
Original Assignee
Lexicon Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lexicon Pharmaceuticals Inc filed Critical Lexicon Pharmaceuticals Inc
Publication of SG11201405563VA publication Critical patent/SG11201405563VA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
SG11201405563VA 2012-03-09 2013-03-05 Imidazo [1, 2 - b] pyridazine - based compounds, compositions comprising them, and uses thereof SG11201405563VA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261608758P 2012-03-09 2012-03-09
PCT/US2013/029043 WO2013134219A1 (en) 2012-03-09 2013-03-05 Imidazo [1, 2 - b] pyridazine - based compounds, compositions comprising them, and uses thereof

Publications (1)

Publication Number Publication Date
SG11201405563VA true SG11201405563VA (en) 2014-10-30

Family

ID=48014284

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201405563VA SG11201405563VA (en) 2012-03-09 2013-03-05 Imidazo [1, 2 - b] pyridazine - based compounds, compositions comprising them, and uses thereof

Country Status (20)

Country Link
US (3) US8969565B2 (ja)
EP (1) EP2822559B1 (ja)
JP (1) JP6418949B2 (ja)
KR (1) KR102085121B1 (ja)
CN (1) CN104470523B (ja)
AR (1) AR090291A1 (ja)
AU (1) AU2013230119B2 (ja)
BR (1) BR112014022271B1 (ja)
CA (1) CA2866164C (ja)
ES (1) ES2676826T3 (ja)
HK (1) HK1203407A1 (ja)
IL (1) IL234485A (ja)
MX (1) MX347917B (ja)
NZ (1) NZ630719A (ja)
RU (1) RU2014140739A (ja)
SG (1) SG11201405563VA (ja)
TW (1) TW201341385A (ja)
UY (1) UY34669A (ja)
WO (1) WO2013134219A1 (ja)
ZA (1) ZA201406148B (ja)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2210891A1 (en) * 2009-01-26 2010-07-28 Domain Therapeutics New adenosine receptor ligands and uses thereof
PT3409278T (pt) 2011-07-21 2020-12-18 Sumitomo Dainippon Pharma Oncology Inc Inibidores de proteína cinase heterocíclicos
US8946415B2 (en) 2012-03-09 2015-02-03 Lexicon Pharmaceuticals, Inc. Pyrazolo[1,5-a]pyrimidine-based compounds, compositions comprising them, and methods of their use
US8901305B2 (en) 2012-07-31 2014-12-02 Bristol-Myers Squibb Company Aryl lactam kinase inhibitors
EP2958924B1 (en) 2013-02-22 2016-12-28 Bristol-Myers Squibb Company 5h-chromeno[3,4-c]pyridines as inhibitors of adaptor associated kinase 1 (aak1)
AR097543A1 (es) * 2013-09-06 2016-03-23 Lexicon Pharmaceuticals Inc COMPUESTOS BASADOS EN IMIDAZO[1,2-b]PIRIDAZINA, COMPOSICIONES QUE LOS COMPRENDEN Y SUS MÉTODOS DE USO
US9737542B2 (en) 2013-10-11 2017-08-22 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
WO2015089143A1 (en) * 2013-12-10 2015-06-18 Bristol-Myers Squibb Company Imidazopyridazine compounds useful as modulators of il-12, il-23 and/or ifn alpha responses
DK3572416T3 (da) * 2014-01-24 2022-12-12 Turning Point Therapeutics Inc Diaryl-makrocykler som modulatorer af proteinkinaser
ES2701903T3 (es) * 2014-01-31 2019-02-26 Bristol Myers Squibb Co Inhibidores de cinasa a base de quinolina
TW201620911A (zh) * 2014-03-17 2016-06-16 雷西肯製藥股份有限公司 銜接子關聯激酶１之抑制劑、包含其之組成物、及其使用方法
US20170239249A1 (en) * 2014-09-30 2017-08-24 Bristol-Myers Squibb Company Quinazoline-based kinase inhibitors
AU2015342883B2 (en) 2014-11-06 2020-07-02 Bial - R&D Investments, S.A. Substituted pyrrolo(1,2-a)pyrimidines and their use in the treatment of medical disorders
EP3215510B1 (en) 2014-11-06 2023-06-07 Bial-R&D Investments, S.A. Substituted imidazo[1,5-a]pyrimidines and their use in the treatment of medical disorders
CN115925711A (zh) 2014-11-06 2023-04-07 Bial研发投资股份有限公司 取代的吡唑并[1,5-a]嘧啶以及它们在治疗医学障碍中的用途
WO2016164295A2 (en) 2015-04-10 2016-10-13 Bristol-Myers Squibb Company Fused pyridines as kinase inhibitors
AU2016287568B2 (en) 2015-07-02 2020-08-20 Turning Point Therapeutics, Inc. Chiral diaryl macrocycles as modulators of protein kinases
MX2017017081A (es) * 2015-07-06 2018-08-16 Tp Therapeutics Inc Polimorfo de macrociclo de diarilo.
KR20180033194A (ko) 2015-07-21 2018-04-02 티피 테라퓨틱스, 인크. 키랄 디아릴 매크로사이클 및 이것의 용도
JP6843135B2 (ja) * 2015-11-18 2021-03-17 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ ＩＬ−１２、ＩＬ−２３および／またはＩＦＮα応答のモジュレーターとして有用なイミダゾピリダジン化合物
CA3020305A1 (en) 2016-04-06 2017-10-12 Lysosomal Therapeutics Inc. Imidazo [1,5-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders
MX2018012207A (es) 2016-04-06 2019-03-28 Lysosomal Therapeutics Inc Compuestos de pirrol[1,2-a]pirimidinil carboxamida y su uso en el tratamiento de trastornos médicos.
KR20180133461A (ko) 2016-04-06 2018-12-14 리소소말 테라퓨틱스 인크. 피라졸로[1,5-a]피리미디닐 카르복스아미드 화합물 및 의학적 장애의 치료에서의 그의 용도
HUE063042T2 (hu) * 2016-04-15 2023-12-28 Blueprint Medicines Corp Az aktivin receptorszerû kináz inhibitorai
EP3452455A4 (en) 2016-05-05 2019-11-13 Lysosomal Therapeutics Inc. SUBSTITUTED IMDAZO [1,2-] PYRIDINES, SUBSTITUTED IMIDAZO [1,2-] PYRAZINES, RELATED COMPOUNDS AND THEIR USE IN THE TREATMENT OF ILLNESSES
US11168087B2 (en) 2016-05-05 2021-11-09 Bial—R&D Investments, S.A. Substituted imidazo[1,2-b]pyridazines, substituted imidazo[1,5-b]pyridazines, related compounds, and their use in the treatment of medical disorders
KR20190034225A (ko) 2016-07-28 2019-04-01 티피 테라퓨틱스, 인크. 거대환 키나제 억제제
GB201617758D0 (en) 2016-10-20 2016-12-07 Almac Discovery Limited Pharmaceutical compounds
TWI808958B (zh) 2017-01-25 2023-07-21 美商特普醫葯公司 涉及二芳基巨環化合物之組合療法
KR20180088113A (ko) * 2017-01-26 2018-08-03 한미약품 주식회사 이미다조피리다진 화합물
EP4101853A1 (en) 2017-03-14 2022-12-14 Daiichi Sankyo Company, Limited Method for producing 3,6-disubstituted-imidazo[1,2-b]pyridazine derivative
CN107082828B (zh) * 2017-05-19 2019-09-17 暨南大学 一种活性氧响应性高分子载体及其制备方法
AU2018306328B2 (en) 2017-07-28 2023-03-09 Turning Point Therapeutics, Inc. Macrocyclic compounds and uses thereof
US10899733B2 (en) 2017-08-23 2021-01-26 Oregon Health & Science University Inhibitors of PARPs that catalyze mono-ADP-ribosylation
KR20200101358A (ko) 2017-12-19 2020-08-27 터닝 포인트 테라퓨틱스, 인크. 질병 치료용 대환식 화합물
JP2022520361A (ja) 2019-02-12 2022-03-30 スミトモ ダイニッポン ファーマ オンコロジー， インコーポレイテッド 複素環式タンパク質キナーゼ阻害剤を含む製剤
CN110684028B (zh) * 2019-10-28 2021-10-26 上海阿拉丁生化科技股份有限公司 一种2，6-二氮杂双环[3，3，0]辛烷类化合物的制备方法
US20230159542A1 (en) * 2020-04-21 2023-05-25 The Uab Research Foundation Rna-binding protein multimerization inhibitors and methods of use thereof
KR102590444B1 (ko) * 2020-10-16 2023-10-18 김홍렬 Pmca 억제제를 포함하는 코로나바이러스 감염 또는 감염 질환의 치료용 조성물
KR102590438B1 (ko) * 2020-10-16 2023-10-18 김홍렬 Pmca 억제제를 포함하는 코로나바이러스 감염 또는 감염 질환의 예방 또는 소독용 조성물
JP2024506909A (ja) * 2021-02-12 2024-02-15 ニンバス サターン， インコーポレイテッド Ｈｐｋ１アンタゴニスト及びその使用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5464764A (en) 1989-08-22 1995-11-07 University Of Utah Research Foundation Positive-negative selection methods and vectors
AU2515992A (en) 1991-08-20 1993-03-16 Genpharm International, Inc. Gene targeting in animal cells using isogenic dna constructs
US20070049591A1 (en) 2005-08-25 2007-03-01 Kalypsys, Inc. Inhibitors of MAPK/Erk Kinase
US7750000B2 (en) * 2005-09-02 2010-07-06 Bayer Schering Pharma Ag Substituted imidazo[1,2b]pyridazines as kinase inhibitors, their preparation and use as medicaments
US20070078136A1 (en) * 2005-09-22 2007-04-05 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
WO2008030579A2 (en) * 2006-09-07 2008-03-13 Biogen Idec Ma Inc. Irak modulators for treating an inflammatory condition, cell proliferative disorder, immune disorder
KR20090075714A (ko) * 2006-10-30 2009-07-08 노파르티스 아게 소염제로서의 헤테로시클릭 화합물
FR2934994B1 (fr) * 2008-08-12 2010-09-17 Sanofi Aventis Derives de 2-alkyl-6cycloamino-3-(pyridin-4-yl)imidaz°1,2-b! pyridazine, leur preparation et leur application en therapeutique
RS53350B (en) * 2008-09-22 2014-10-31 Array Biopharma, Inc. SUBSTITUTED COMPOUNDS OF IMIDASO [1,2-B] PYRIDASINE AS INK KINASE INHIBITORS
US8946415B2 (en) 2012-03-09 2015-02-03 Lexicon Pharmaceuticals, Inc. Pyrazolo[1,5-a]pyrimidine-based compounds, compositions comprising them, and methods of their use
ES2657061T3 (es) 2012-03-09 2018-03-01 Lexicon Pharmaceuticals, Inc. Inhibición de la cinasa 1 asociada a adaptador para el tratamiento del dolor

Also Published As

Publication number Publication date
WO2013134219A1 (en) 2013-09-12
MX2014010584A (es) 2014-09-18
HK1203407A1 (en) 2015-10-30
CN104470523B (zh) 2017-07-11
IL234485A (en) 2017-02-28
EP2822559B1 (en) 2018-05-02
US20170057964A1 (en) 2017-03-02
KR20140138865A (ko) 2014-12-04
US20160024093A1 (en) 2016-01-28
JP2015509534A (ja) 2015-03-30
MX347917B (es) 2017-05-17
JP6418949B2 (ja) 2018-11-07
RU2014140739A (ru) 2016-04-27
BR112014022271B1 (pt) 2021-09-21
CA2866164A1 (en) 2013-09-12
AU2013230119B2 (en) 2017-02-23
ZA201406148B (en) 2016-06-29
US20130245021A1 (en) 2013-09-19
TW201341385A (zh) 2013-10-16
NZ630719A (en) 2017-01-27
EP2822559A1 (en) 2015-01-14
AU2013230119A1 (en) 2014-09-25
CN104470523A (zh) 2015-03-25
AR090291A1 (es) 2014-11-05
KR102085121B1 (ko) 2020-03-05
UY34669A (es) 2013-10-31
CA2866164C (en) 2020-07-07
US8969565B2 (en) 2015-03-03
ES2676826T3 (es) 2018-07-25
BR112014022271A2 (ja) 2017-06-20

Similar Documents

Publication Publication Date Title
ZA201406148B (en) Imidazo [1, 2 - b] pyridazine - based compounds, compositions comprising them, and uses thereof
IL279304A (en) History of cytotoxic benzodiazepines, preparations containing them and their uses
IL236075A0 (en) Imidazo [1,2-b] pyridazine kinase inhibitor derivatives, preparations containing them and their uses
IL233154A (en) Compounds, pharmaceuticals containing them and their uses
IL233863A (en) Pyridine derivatives, preparations containing them and their uses
IL228322A0 (en) History of dispiropyrrolidine, preparations containing them and their uses
EP2935264A4 (en) BICYCLIC 1,4-PYRIDONE HETEROARYL COMPOUNDS
AP2014008084A0 (en) Compositions comprising shortacting benzodiazepines
HK1217659A1 (zh) 基於咪唑並 噠嗪的化合物、包含它們的組合物及其使用方法
ZA201404065B (en) Tricyclic compounds, compositions comprising them and uses thereof
IL236712A0 (en) Di-teri-heteroaryl derivatives, preparations containing them and their uses
EP2935280A4 (en) 8'-HYDROXY-DIHYDROERGOTAMINE COMPOUNDS AND COMPOSITIONS
IL233824A (en) Compounds 1h - Indazole - 3 - Carboxamide, preparations containing them and their use
IL232061A (en) The heterocyclic compound in the bicycle, a pharmaceutical product containing it and its use
EP2903979A4 (en) Novel compounds, their preparation and use
IL233682A0 (en) Modified phenylazole derivatives, preparations containing them and their uses
IL280316B (en) Amphiphilic compounds, preparations and their use
IL237542A0 (en) Amphiphilic compounds, their preparations and uses
IL236568A0 (en) Uses of alkylthiophene-rich compositions and methods of creating these compositions
IL238461A0 (en) 1 hindole-3-carboxamide derivatives and their use as p2y12 inhibitors
IL237540A0 (en) Amphiphilic compounds, their preparations and uses
IL237538A0 (en) Amphiphilic compounds, their preparations and uses
IL237539A0 (en) Amphiphilic compounds, their preparations and uses
IL232620A0 (en) Tricyclic compounds, preparations including them and their use